Based on the discoveries and inventions made by my lab together with Prof. Ofer Mandelboim from the Immunology & Cancer Research Center at the Hebrew University in 2017, we established company Nectin Therapeutics (http://www.nectintx.com/) together with Integra Holdings & Yissum as the key shareholders. Nectin Therapeutics is developing novel therapeutics based on monoclonal antibodies directed towards members of the Nectin family of receptors and their ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy.
Licencing of new monoclonal antibodies for scientific research and commercialization: Center for proteomics is in possession of several hundred well-defined monoclonal antibodies against viral and cellular proteins, some of which are subject of licencing in collaboration with various biotech companies and other partners. Several of these antibodies have already been subject of patent application.
© Copyright 2023 | All rights reserved | Web development: Intraweb d.o.o.